Impact of emergency department management of isolated superficial vein thrombosis of the lower limbs: a secondary analysis of data from the ALTAMIRA study.

Fahd Beddar Chaib, Sònia Jiménez Hernández, José María Pedrajas Navas, Ramón Lecumberri, Leticia Guirado Torrecillas, Héctor Alonso Valle, Susana Diego Roza, Vanesa Sendín Martín, Mª Angélica Rivera Núñez, Jorge Pedraza García, Daniel Sánchez Díaz-Canel, Pedro Ruiz Artacho
{"title":"Impact of emergency department management of isolated superficial vein thrombosis of the lower limbs: a secondary analysis of data from the ALTAMIRA study.","authors":"Fahd Beddar Chaib, Sònia Jiménez Hernández, José María Pedrajas Navas, Ramón Lecumberri, Leticia Guirado Torrecillas, Héctor Alonso Valle, Susana Diego Roza, Vanesa Sendín Martín, Mª Angélica Rivera Núñez, Jorge Pedraza García, Daniel Sánchez Díaz-Canel, Pedro Ruiz Artacho","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To describe the management of superficial vein thrombosis (SVT) of the lower limbs in patients treated in Spanish hospital emergency departments (EDs). To evaluate the impact of ED management of venous thromboembolic complications on outcomes and to determine the characteristics of patients who develop complications.</p><p><strong>Material and methods: </strong>The retrospective multicenter ALTAMIRA study (Spanish acronym for risk factors, complications, and assessment of Spanish ED management of SVT) used recorded data for consecutive patients with a diagnosis of isolated SVT treated in 18 EDs. We gathered data on symptomatic venous thromboembolic disease (deep vein thrombosis, pulmonary embolism, or the extension or recurrence of SVT), clinically significant bleeding, and 180-day mortality. Cox regression analysis was used to explore variables associated with complications.</p><p><strong>Results: </strong>A total of 703 patients were included. Anticoagulation was prescribed for 84.1% of the patients for a median of 30 days (interquartile range, 15-42 days); 81.3% were treated with low molecular weight heparin. A prophylactic dose was prescribed for 48% and an intermediate therapeutic dose for 52%. Sixty-four patients (9.2%) developed symptomatic thromboembolic disease within 180 days, 12 (1.7%) experienced clinically significant bleeding, and 4 (0.6%) died. Complications developed later in patients receiving anticoagulant therapy than in those not taking an anticoagulant (66 vs 11 days , P=.009), and 76.6% of those developing complications were not on anticoagulant when symptoms appeared. A history of thromboembolic disease was associated with developing complications (adjusted hazard ratio, 2.20; 95% confidence interval, 1.34-3.62).</p><p><strong>Conclusion: </strong>ED treatment of SVT varies and is often suboptimal. The incidence of thromboembolic complications after SVT is high. Starting anticoagulation in the ED delays the development of complications. Patients with a history of thromboembolic disease are more at risk of complications.</p>","PeriodicalId":11644,"journal":{"name":"Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias","volume":"35 2","pages":"109-116"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To describe the management of superficial vein thrombosis (SVT) of the lower limbs in patients treated in Spanish hospital emergency departments (EDs). To evaluate the impact of ED management of venous thromboembolic complications on outcomes and to determine the characteristics of patients who develop complications.

Material and methods: The retrospective multicenter ALTAMIRA study (Spanish acronym for risk factors, complications, and assessment of Spanish ED management of SVT) used recorded data for consecutive patients with a diagnosis of isolated SVT treated in 18 EDs. We gathered data on symptomatic venous thromboembolic disease (deep vein thrombosis, pulmonary embolism, or the extension or recurrence of SVT), clinically significant bleeding, and 180-day mortality. Cox regression analysis was used to explore variables associated with complications.

Results: A total of 703 patients were included. Anticoagulation was prescribed for 84.1% of the patients for a median of 30 days (interquartile range, 15-42 days); 81.3% were treated with low molecular weight heparin. A prophylactic dose was prescribed for 48% and an intermediate therapeutic dose for 52%. Sixty-four patients (9.2%) developed symptomatic thromboembolic disease within 180 days, 12 (1.7%) experienced clinically significant bleeding, and 4 (0.6%) died. Complications developed later in patients receiving anticoagulant therapy than in those not taking an anticoagulant (66 vs 11 days , P=.009), and 76.6% of those developing complications were not on anticoagulant when symptoms appeared. A history of thromboembolic disease was associated with developing complications (adjusted hazard ratio, 2.20; 95% confidence interval, 1.34-3.62).

Conclusion: ED treatment of SVT varies and is often suboptimal. The incidence of thromboembolic complications after SVT is high. Starting anticoagulation in the ED delays the development of complications. Patients with a history of thromboembolic disease are more at risk of complications.

急诊科管理对孤立性下肢浅静脉血栓形成的影响:对ALTAMIRA研究数据的二次分析。
目的:描述在西班牙医院急诊科(ED)接受治疗的患者下肢浅静脉血栓形成(SVT)的处理。评估静脉血栓栓塞并发症的ED治疗对结果的影响,并确定出现并发症的患者的特征。材料和方法:回顾性多中心ALTAMIRA研究(西班牙语中SVT的危险因素、并发症和西班牙ED管理评估的缩写)使用了连续18例ED中诊断为孤立性SVT的患者的记录数据。我们收集了症状性静脉血栓栓塞疾病(深静脉血栓形成、肺栓塞或SVT的延长或复发)、临床显著出血和180天死亡率的数据。Cox回归分析用于探讨与并发症相关的变量。结果:共纳入703例患者。84.1%的患者接受了抗凝治疗,平均时间为30天(四分位间距,15-42天);81.3%用低分子肝素治疗。预防剂量为48%,中间治疗剂量为52%。64名患者(9.2%)在180天内出现症状性血栓栓塞疾病,12名患者(1.7%)出现临床显著出血,4名患者(0.6%)死亡。接受抗凝剂治疗的患者比未服用抗凝剂的患者出现并发症的时间晚(66天vs 11天,P=.009),76.6%的出现并发症的患者在出现症状时没有服用抗凝剂。血栓栓塞病史与并发症的发生有关(调整后的危险比为2.20;95%置信区间为1.34-3.62)。SVT后血栓栓塞并发症的发生率很高。ED开始抗凝治疗可延缓并发症的发展。有血栓栓塞病史的患者更容易发生并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信